Ascendis Pharma to Participate in the TD Cowen 45th Annual Health Care Conference
Ascendis Pharma A/S (Nasdaq: ASND) has announced its participation in the TD Cowen 45th Annual Health Care Conference. Company executives will engage in a fireside chat scheduled for Tuesday, March 4, 2025, at 11:10 a.m. Eastern Time / 8:10 a.m. Pacific Time in Boston, Massachusetts.
The event will be accessible through a live webcast on the Investors & News section of the Ascendis Pharma website at investors.ascendispharma.com. For those unable to attend live, a replay of the webcast will be available on the same website for 30 days following the event.
Ascendis Pharma A/S (Nasdaq: ASND) ha annunciato la sua partecipazione alla 45ª Conferenza Annuale sulla Salute di TD Cowen. I dirigenti dell'azienda parteciperanno a una conversazione informale programmata per martedì 4 marzo 2025, alle 11:10 ora orientale / 8:10 ora del Pacifico a Boston, Massachusetts.
L'evento sarà accessibile tramite un webcast dal vivo nella sezione Investitori & News del sito web di Ascendis Pharma all'indirizzo investors.ascendispharma.com. Per coloro che non possono partecipare dal vivo, una registrazione del webcast sarà disponibile sullo stesso sito per 30 giorni dopo l'evento.
Ascendis Pharma A/S (Nasdaq: ASND) ha anunciado su participación en la 45ª Conferencia Anual de Salud de TD Cowen. Los ejecutivos de la empresa participarán en una charla informal programada para el martes 4 de marzo de 2025, a las 11:10 a.m. hora del Este / 8:10 a.m. hora del Pacífico en Boston, Massachusetts.
El evento será accesible a través de un webcast en vivo en la sección de Inversores y Noticias del sitio web de Ascendis Pharma en investors.ascendispharma.com. Para aquellos que no puedan asistir en vivo, se dispondrá de una repetición del webcast en el mismo sitio durante 30 días después del evento.
Ascendis Pharma A/S (Nasdaq: ASND)는 TD Cowen 제45회 연례 헬스케어 컨퍼런스에 참여한다고 발표했습니다. 회사 임원들은 2025년 3월 4일 화요일, 동부 표준시 기준 오전 11시 10분 / 태평양 표준시 기준 오전 8시 10분에 매사추세츠주 보스턴에서 진행되는 파이어사이드 챗에 참여할 예정입니다.
이 행사는 Ascendis Pharma 웹사이트의 투자자 및 뉴스 섹션에서 실시간 웹캐스트를 통해 접속할 수 있습니다. 실시간 참석이 불가능한 분들을 위해, 행사 후 30일 동안 같은 웹사이트에서 웹캐스트 재생이 제공될 예정입니다.
Ascendis Pharma A/S (Nasdaq: ASND) a annoncé sa participation à la 45e Conférence Annuelle sur la Santé de TD Cowen. Les dirigeants de l'entreprise participeront à une discussion informelle prévue pour mardi 4 mars 2025, à 11h10 heure de l'Est / 8h10 heure du Pacifique à Boston, Massachusetts.
L'événement sera accessible via un webinaire en direct dans la section Investisseurs & Actualités du site web d'Ascendis Pharma à l'adresse investors.ascendispharma.com. Pour ceux qui ne peuvent pas assister en direct, un replay du webinaire sera disponible sur le même site pendant 30 jours après l'événement.
Ascendis Pharma A/S (Nasdaq: ASND) hat seine Teilnahme an der 45. jährlichen Gesundheitskonferenz von TD Cowen bekannt gegeben. Unternehmensleiter werden an einem informellen Gespräch teilnehmen, das für Dienstag, den 4. März 2025, um 11:10 Uhr Eastern Time / 8:10 Uhr Pacific Time in Boston, Massachusetts, geplant ist.
Die Veranstaltung wird über einen Live-Webcast im Bereich Investoren & Nachrichten der Ascendis Pharma-Website unter investors.ascendispharma.com zugänglich sein. Für diejenigen, die nicht live teilnehmen können, wird eine Wiederholung des Webcasts auf derselben Website 30 Tage nach der Veranstaltung verfügbar sein.
- None.
- None.
COPENHAGEN, Denmark, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Tuesday, March 4, 2025, at 11:10 a.m. Eastern Time / 8:10 a.m. Pacific Time in Boston, Massachusetts.
A live webcast of the presentation will be available via the Investors & News section of the Ascendis Pharma website at investors.ascendispharma.com. A webcast replay will also be available on this website shortly after conclusion of the event for 30 days.
About Ascendis Pharma A/S
Ascendis Pharma is applying its innovative TransCon technology platform to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients’ lives. Guided by its core values of Patients, Science, and Passion, Ascendis uses its TransCon technologies to create new and potentially best-in-class therapies. Ascendis is headquartered in Copenhagen, Denmark and has additional facilities in Europe and the United States. Please visit ascendispharma.com to learn more.
Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Ascendis’ future operations, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to (i) Ascendis’ ability to apply its innovative TransCon technology platform to build a leading, fully integrated biopharma company, and (ii) Ascendis’ use of its TransCon technologies to create new and potentially best-in-class therapies. Ascendis may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Ascendis makes, including the following: dependence on third party manufacturers, distributors and service providers for Ascendis’ products and product candidates; unforeseen safety or efficacy results in Ascendis’ development programs or on-market products; unforeseen expenses related to commercialization of any approved Ascendis products; unforeseen expenses related to Ascendis’ development programs; unforeseen selling, general and administrative expenses, other research and development expenses and Ascendis’ business generally; delays in the development of its programs related to manufacturing, regulatory requirements, speed of patient recruitment or other unforeseen delays; Ascendis’ ability to obtain additional funding, if needed, to support its business activities; the impact of international economic, political, legal, compliance, social and business factors. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ascendis’ business in general, see Ascendis’ Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (SEC) on February 12, 2025, and Ascendis’ other future reports filed with, or submitted to, the SEC. Forward-looking statements do not reflect the potential impact of any future licensing, collaborations, acquisitions, mergers, dispositions, joint ventures, or investments that Ascendis may enter into or make. Ascendis does not assume any obligation to update any forward-looking statements, except as required by law.
Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo and TransCon are trademarks owned by the Ascendis Pharma group. © February 2025 Ascendis Pharma A/S.
| Investor Contacts: Scott Smith Ascendis Pharma ir@ascendispharma.com | Media Contact: Melinda Baker Ascendis Pharma +1 (650) 709-8875 media@ascendispharma.com |
| Patti Bank ICR Healthcare +1 (415) 513-1284 patti.bank@icrhealthcare.com |
FAQ
When is Ascendis Pharma (ASND) presenting at the TD Cowen Healthcare Conference 2025?
How can investors watch Ascendis Pharma's (ASND) TD Cowen conference presentation?
How long will the replay of ASND's TD Cowen conference presentation be available?
Where is the TD Cowen Healthcare Conference 2025 with ASND being held?
